Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study

Complete molecular profiling in PDAC patients ≤ 60 years showed moderate success (55 %) and limited clinical impact, with actionable findings in 13 % and therapy implementation in 3.5 %. Prioritizing KRAS testing and deeper sequencing in KRAS-wildtype tumors, alongside broader access to targeted therapies, may improve outcomes.

Authors

Institutions

Publication Details

Journal
European Journal of Cancer
Published
2025-10-19
DOI
https://doi.org/10.1016/j.ejca.2025.116065
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study

Gaby J. Strijk, Casper H.J. van Eijck, Floris H. Groenendijk, Nigel G. Kooreman et al.
European Journal of Cancer
Pancreatic and Hepatic Oncology Research
article

Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study

Gaby J. Strijk, Casper H.J. van Eijck, Floris H. Groenendijk, Nigel G. Kooreman, Sanne R. Martens‐de Kemp, Judith de Vos‐Geelen, Lodewijk A.A. Brosens, Arantza Fariña Sarasqueta, Geert A. Cirkel, Willem de Koning, Ignace H. J. T. de Hingh, Marjolein Y.V. Homs, Jelle C. van Dongen, Anja Wagner, Andrew Stubbs, Michail Doukas, Johanna W. Wilmink, Prof Bas Groot Koerkamp
article en

Abstract

Complete molecular profiling in PDAC patients ≤ 60 years showed moderate success (55 %) and limited clinical impact, with actionable findings in 13 % and therapy implementation in 3.5 %. Prioritizing KRAS testing and deeper sequencing in KRAS-wildtype tumors, alongside broader access to targeted therapies, may improve outcomes.

European Journal of CancerVol. 230
Radboud University Nijmegen (NL), Maastricht University Medical Centre (NL), Catharina Ziekenhuis (NL), Radboud University Medical Center (NL), University Medical Center Utrecht (NL), Amsterdam Neuroscience (NL), Erasmus MC Cancer Institute (NL), Amsterdam University Medical Centers (NL), Meander Medisch Centrum (NL), Amsterdam University of Applied Sciences (NL), University of Amsterdam (NL)
Openalex Percentile: Top 60%
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.